Comprehensive medication guide to Tetrabenazine including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$50–$200/month copay on most commercial insurance plans (Tier 4–5 specialty drug); Medicare Part D patients have an annual out-of-pocket cap of $2,000 starting 2025; prior authorization required by most plans.
Estimated Cash Pricing
$60–$65 per month with GoodRx or SingleCare coupon for generic tetrabenazine; up to $4,000–$4,400/month at full retail list price without any discount program for a 30-day supply.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Tetrabenazine (brand name Xenazine) is a prescription oral medication classified as a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). It was FDA-approved on August 15, 2008, making it the first medication ever approved in the United States specifically for the treatment of chorea associated with Huntington's disease (HD).
Tetrabenazine is available as oral tablets in 12.5 mg and 25 mg strengths. It does not cure Huntington's disease or slow its progression — it provides symptomatic relief by reducing the severity of the involuntary, irregular dance-like movements known as chorea that are a hallmark of HD.
Generic tetrabenazine is available from multiple manufacturers and is bioequivalent to brand Xenazine. With discount coupons, the generic can cost as little as $60 per fill — a dramatic reduction from the $4,000+ retail list price.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Tetrabenazine works by reversibly inhibiting VMAT2 — a protein inside neurons that packages monoamine neurotransmitters (dopamine, serotonin, norepinephrine, and histamine) into synaptic vesicles for storage and release. By blocking VMAT2, tetrabenazine prevents these neurotransmitters from being packaged and stored properly.
Without adequate packaging into vesicles, the neurotransmitters — especially dopamine — are exposed to metabolic enzymes that break them down. As a result, when a nerve signal arrives, there is significantly less dopamine available to release into the synapse. This reduction in dopamine activity in the basal ganglia helps restore movement control and reduces the involuntary choreiform movements of Huntington's disease.
This mechanism is reversible — when the drug wears off between doses, neurotransmitter levels recover. Chorea symptoms typically return within 12–18 hours of the last dose if the medication is stopped.
12.5 mg — tablet
Starting dose and titration increment; white or yellowish tablet
25 mg — tablet
Maintenance dose; yellowish-buff scored tablet; max single dose is 25 mg for poor CYP2D6 metabolizers, 37.5 mg for extensive metabolizers
As of 2026, Tetrabenazine is not listed on the FDA's Drug Shortage Database as being in a national shortage. Generic tetrabenazine is manufactured by multiple companies, and the original brand Xenazine remains available through specialty pharmacy channels. However, patients frequently report difficulty finding it at standard retail pharmacies.
The core challenge is structural: Tetrabenazine treats Huntington's disease, a rare condition affecting approximately 30,000 Americans. Because very few patients in any given area use it, most retail chain pharmacies don't stock it routinely. Specialty pharmacies (CVS Specialty, Accredo, Walgreens Specialty) maintain more reliable stock and are the preferred dispensing channel for this medication.
If you're struggling to find Tetrabenazine at your pharmacy, medfinder calls pharmacies in your area to locate which ones have it in stock and texts you the results — saving you hours of calls.
Because Tetrabenazine is not a controlled substance, any licensed physician, nurse practitioner (NP), or physician assistant (PA) can legally prescribe it. However, given its boxed warning for depression and suicidality and the clinical complexity of managing Huntington's disease, it is almost exclusively prescribed by specialists.
Common prescriber types for Tetrabenazine:
Movement disorder neurologists (primary specialists)
General neurologists with HD experience
Psychiatrists managing Huntington's disease psychiatric symptoms
NPs and PAs working in neurology practices
Because Tetrabenazine is not a controlled substance, it can be prescribed via telehealth visits in all 50 states for ongoing management. Initial diagnosis of Huntington's disease typically requires at least one in-person evaluation, but stable patients on established Tetrabenazine regimens can often receive refills and dose adjustments via telemedicine.
No. Tetrabenazine is not a controlled substance under the DEA Controlled Substances Act. It has no DEA schedule. Clinical trials did not show patients developing drug-seeking behaviors, and postmarketing surveillance in multiple countries where tetrabenazine has been used for decades has not revealed abuse potential.
Because it is not a controlled substance, Tetrabenazine can be prescribed and refilled without the special DEA-number restrictions that apply to Schedule II–V medications. Prescriptions can be sent electronically, written in advance, and refilled without the quantity limits that govern controlled substances. Telehealth prescribing is also permitted in all states without additional federal restrictions.
Boxed Warning: Tetrabenazine carries an FDA boxed warning for increased risk of depression and suicidal thinking in Huntington's disease patients. It is contraindicated in patients who are actively suicidal or have untreated depression.
Common side effects include:
Somnolence and sedation
Depression and worsening mood
Anxiety and nervousness
Nausea
Insomnia
Akathisia (inner restlessness)
Parkinsonism (tremor, rigidity, bradykinesia, balance problems)
Orthostatic hypotension (dizziness when standing)
Serious side effects requiring immediate medical attention:
Suicidal thoughts or behaviors — call 911 or go to ER immediately
Neuroleptic Malignant Syndrome (NMS): high fever, severe muscle rigidity, fast heartbeat, sweating, confusion
QT prolongation / cardiac arrhythmia
Dysphagia (difficulty swallowing)
Know what you need? Skip the search.
Deutetrabenazine (Austedo, Austedo XR)
Next-generation VMAT2 inhibitor FDA-approved for HD chorea and tardive dyskinesia. Longer half-life (9–11 hours), allows twice-daily or once-daily (XR) dosing. Potentially better tolerated than tetrabenazine but not yet available as generic; significantly higher cost without insurance.
Valbenazine (Ingrezza)
VMAT2 inhibitor approved for tardive dyskinesia and HD chorea with convenient once-daily dosing. Cannot be taken concurrently with tetrabenazine. Brand-only; no generic available. Manufactured by Neurocrine Biosciences.
Haloperidol (Haldol)
Older antipsychotic used off-label for HD chorea before tetrabenazine was approved. Widely available as generic at low cost, but risk of tardive dyskinesia with long-term use and significant extrapyramidal side effects.
Olanzapine (Zyprexa)
Atypical antipsychotic used off-label for HD symptoms including chorea, particularly in patients with co-occurring psychiatric symptoms. Generic available; lower EPS risk than haloperidol but causes metabolic effects and weight gain.
Prefer Tetrabenazine? We can find it.
MAOIs (phenelzine, tranylcypromine, isocarboxazid, linezolid)
majorContraindicated combination. Risk of severe acute hypertensive crisis. At least 14 days must elapse after stopping an MAOI before starting tetrabenazine.
Reserpine
majorContraindicated. Combined use causes excessive CNS depletion of serotonin and norepinephrine. At least 20 days must elapse after stopping reserpine before starting tetrabenazine.
Deutetrabenazine (Austedo) or Valbenazine (Ingrezza)
majorContraindicated concurrent use due to additive VMAT2 inhibition. Austedo can be started the day after stopping tetrabenazine.
Fluoxetine (Prozac) or Paroxetine (Paxil)
majorStrong CYP2D6 inhibitors that markedly increase exposure to tetrabenazine active metabolites (alpha- and beta-HTBZ). Dose adjustment required; treat patient as poor CYP2D6 metabolizer.
QT-prolonging agents (antipsychotics, Class 1A/III antiarrhythmics, moxifloxacin, methadone)
majorAdditive QT prolongation increases risk of torsade de pointes and cardiac arrhythmias. Avoid combination or monitor closely with ECG.
CNS depressants (opioids, benzodiazepines, alcohol, sleep medications)
moderateAdditive sedation and CNS depression. Avoid alcohol; use caution with other sedating medications.
Bupropion (Wellbutrin)
moderateModerate CYP2D6 inhibitor; may increase tetrabenazine metabolite exposure. Use with caution.
Tetrabenazine (Xenazine) remains a cornerstone treatment for chorea in Huntington's disease in 2026. As the first FDA-approved medication specifically for HD, it has a well-established clinical track record spanning more than 15 years of use in the United States. The availability of generic tetrabenazine has significantly improved affordability — with discount programs reducing costs from $4,000+ to as little as $60 per fill.
The main challenges with Tetrabenazine in 2026 are not shortages or production problems, but rather structural barriers: most retail pharmacies don't stock it, insurance prior authorizations require advance planning, and the boxed warning for depression demands ongoing clinical monitoring. Patients and caregivers who navigate these challenges — by using specialty pharmacies, refilling early, and staying connected with their neurologist — can maintain reliable access.
If you're struggling to find Tetrabenazine at your pharmacy, medfinder can help. Enter your medication, dosage, and location, and medfinder calls pharmacies near you to find which ones can fill your prescription — then texts you the results.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini